CA-NEXON-AMERICA-INC.
17.3.2022 14:03:02 CET | Business Wire | Press release
MapleStory , the popular free-to-play global MMORPG from Nexon , has today announced that the latest update Double Trouble Superstars is now live. The update adds offerings with Yeti and Pink Bean World character creation, which also brings boosts to the game along with special events, the Singles’ and Couples’ Army, along with major rewards to be earned! This update also brings the long-awaited 64-bit client to Nexon's Launcher; Maplers should notice improved game client performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005416/en/
One of the most anticipated events is coming to MapleStory; Yeti x Pink Bean World. Players can create 1 Yeti and 1 Pink Bean character in the dedicated world and get a skill that grants boosts such as 50% more EXP and 30% more damage to all monsters. These boosts are not the only rewards for participation! By diving into the various events like the Monster Punch King Event and Step Up Event , players will earn fascinating rewards like Mega Character Burninator , Growth Potions , Pink Bean/Yeti Titles , Pink Bean/Yeti themed Damage Skins , and place in the Monster Punch King Event rankings to get Maple Points rewards.
Even though players don’t have to choose between Yeti and Pink Bean, they must choose between Singles’ Army and Couples’ Army . The Armies are competing against each other to build the biggest statue, and each player will take a side to help build the statue by donating the material, Spring Energy, which can be obtained from slaying monsters or getting hearts that rain down on major town maps during Solo and Couple Time. Various in-game items such as Invincible Singles' Army OR Loving Couples' Army Item Set , Singles' Army OR Couples' Army Damage Skin , and Singles' Army OR Couples' Army Statue Chair will be awarded to the members of the Armies based on the completion status of the statues.
The final event will be the one players are looking for in order to expedite the growth of their characters. In addition, players can get the Hasty Hunting Box by completing daily haste missions. In addition to the various rewards in the box, simply opening a box will allow players to experience faster hunting with Haste Boosters.
Last but certainly not least, MapleStory is offering a set of special rewards for Maplers who play on GeForce NOW cloud gaming service from March 25 to April 29. As a thank you for playing on Nvidia’s cloud gaming service, level 30 Maplers logging in to MapleStory using GeForce Now will receive a specific “GeForce Now” quest that grants players a Lil Boo Pet, plus a GFN Event Box that can be opened twenty-four hours after acquiring.
This update also brings a meaningful overhaul to the game client by updating to 64-bit when launching from the Nexon Launcher. (MapleStory players on Steam can expect the 64-bit client in an upcoming release.) Double Trouble Superstars lets players experience a better MapleStory than ever before!
Assets: HERE
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005416/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom